Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
- PMID: 8551612
- PMCID: PMC189876
- DOI: 10.1128/JVI.70.2.753-762.1996
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
Abstract
The humoral immune response to human immunodeficiency virus type 1 (HIV-1) is often studied by using monomeric or denatured envelope proteins (Env). However, native HIV-1 Env complexes that maintain quaternary structure elicit immune responses that are qualitatively distinct from those seen with monomeric or denatured Env. To more accurately assess the levels and types of antibodies elicited by HIV-1 infection, we developed an antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. We compared the reactivities of clade B and clade E serum samples to captured Env preparations and found that while both reacted equally well with oligomeric gp140, clade B seras reacted more strongly with monomeric gp120 than did clade E samples. However, these differences were minimized when gp120 was captured by a V3 loop MAb, which may lead to increased exposure of the CD4 binding site. We also measured the ability of serum samples to block binding of MAbs to epitopes in gp120 and gp41. Clade B serum samples consistently blocked binding of oligomer-dependent MAbs to gp41 and, to a slightly lesser extent, MAbs to the CD4 binding site in gp120. Clade E serum samples showed equivalent or greater blocking of oligomer-dependent gp41 antibodies and considerably less blocking of CD4-binding-site MAbs. Finally, we found that < 5% of the antibodies in clade B sera bound to epitopes present only in monomeric gp120, 30% bound to epitopes present in both monomeric gp120 and oligomeric gp140, and 70% bound to epitopes present in oligomeric gp140, which includes gp41. Thus, captured oligomeric Env closely reflects the antigenic characteristics of Env protein on the surface of virions and infected cells, retains highly conserved epitopes that are recognized by antibodies raised against different clades, and makes it possible to detect a much greater fraction of total anti-HIV-1 Env activity in sera than does native monomeric gp120.
Similar articles
-
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.J Virol. 1994 May;68(5):3015-26. doi: 10.1128/JVI.68.5.3015-3026.1994. J Virol. 1994. PMID: 7512157 Free PMC article.
-
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11699-703. doi: 10.1073/pnas.91.24.11699. Proc Natl Acad Sci U S A. 1994. PMID: 7972127 Free PMC article.
-
Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.AIDS Res Hum Retroviruses. 2000 Jul 1;16(10):981-94. doi: 10.1089/08892220050058407. AIDS Res Hum Retroviruses. 2000. PMID: 10890360
-
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.Science. 1998 Jun 19;280(5371):1884-8. doi: 10.1126/science.280.5371.1884. Science. 1998. PMID: 9632381 Review.
-
HIV-1 envelope glycoprotein structure.Curr Opin Struct Biol. 2013 Apr;23(2):268-76. doi: 10.1016/j.sbi.2013.03.007. Epub 2013 Apr 18. Curr Opin Struct Biol. 2013. PMID: 23602427 Free PMC article. Review.
Cited by
-
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.J Virol. 2003 Dec;77(23):12782-94. doi: 10.1128/jvi.77.23.12782-12794.2003. J Virol. 2003. PMID: 14610200 Free PMC article.
-
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.J Virol. 2011 Jun;85(12):5764-72. doi: 10.1128/JVI.00342-11. Epub 2011 Apr 13. J Virol. 2011. PMID: 21490100 Free PMC article.
-
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.J Virol. 2004 Sep;78(17):9317-24. doi: 10.1128/JVI.78.17.9317-9324.2004. J Virol. 2004. PMID: 15308726 Free PMC article.
-
Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.J Virol. 1999 Oct;73(10):8201-15. doi: 10.1128/JVI.73.10.8201-8215.1999. J Virol. 1999. PMID: 10482571 Free PMC article.
-
Recombinant rabies virus as potential live-viral vaccines for HIV-1.Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3544-9. doi: 10.1073/pnas.97.7.3544. Proc Natl Acad Sci U S A. 2000. PMID: 10706640 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials